OBJECTIVES: The main objective was to evaluate the consumption of antidepressants, it s utilization as the basic aspect of the quality of life and to analyze the using of the original drugs or generics and to show the pharmacoeconomical impact of this group of drugs considering to it s financial costingness. METHODS: We used the analysis of consumption trend of antidepressants and the analysis of the trend of prices of antidepressants. We compared the original and generic market with antidepressants in Slovakia, we monitored and compared the prices for DDD and we evaluate the impact of new generics on the prices of originals as well. RESULTS: The consumption of antidepressants has increased because of increasing number depression illnesses which could be continually treated by modern antidepressants since successful treatment depends on relaps prevention. Such outcome could be reached by usage of the latest antidepressants with good compliance (escitalopram, venlafaxine, mirtazapin). Since 2005 the consumption (packages sold) of antidepressant increased by 29% whereas the sales value stagnated as result of declining price. The price for daily recommended dosage decreased by 52.7% (from €0.80 in 2001 to €0.38 in 2008). This was influenced mainly by the increasing number of generics medicaments which pushed the price down. In 2009 the price of original antidepressants fall by 26.4% as reason of generic molecules. Based on long-term surveys the similar trend could be expected also in the future. CONCLUSIONS: The utilization of antidepressants lead to better quality of life. From the pharmacoeconomical view, the development of new molecules goes hand in hand with the decrease of invalidation, decrease of the cost for hospitalization, as well as increase people ´s ability to take care about themselves. On the other hand, the generic substitution leads to increase of the amount of treated patients.